Vectura Group (LON:VEC) Price Target Raised to GBX 134

Vectura Group (LON:VEC) had its price target increased by Peel Hunt from GBX 114 ($1.40) to GBX 134 ($1.65) in a research note issued to investors on Thursday morning, Stock Target Advisor reports. They currently have a buy rating on the stock.

Separately, Shore Capital reissued a hold rating on shares of Vectura Group in a research note on Wednesday, May 27th.

Shares of LON:VEC opened at GBX 99.90 ($1.23) on Thursday. The company’s fifty day moving average is GBX 98.72 and its two-hundred day moving average is GBX 92.06. The company has a quick ratio of 1.77, a current ratio of 2.28 and a debt-to-equity ratio of 1.81. Vectura Group has a 12-month low of GBX 0.93 ($0.01) and a 12-month high of GBX 107 ($1.32). The company has a market cap of $600.18 million and a P/E ratio of -29.38.

In related news, insider Kevin Matthews purchased 12,000 shares of the stock in a transaction dated Tuesday, June 9th. The shares were acquired at an average cost of GBX 92 ($1.13) per share, for a total transaction of £11,040 ($13,586.02). Also, insider Paul Fry sold 106,312 shares of the business’s stock in a transaction on Wednesday, June 3rd. The shares were sold at an average price of GBX 88 ($1.08), for a total transaction of £93,554.56 ($115,129.90).

About Vectura Group

Vectura Group plc engages in the design, development, and supply of pharmaceutical products for the treatment of airways-related diseases worldwide. The company's in-market products include Seebri Breezhaler and Neohaler, a DPI device and bronchodilator; AirFluSal Forspiro for the treatment of asthma and chronic obstructive pulmonary disease (COPD); Breelib for the treatment of pulmonary arterial hypertension; Relvar Ellipta/Breo Ellipta that is used in treating asthma and COPD; and Incruse Ellipta and Anoro Ellipta for the treatment of COPD.

Read More: What are the advantages to having securities held in street name?

Receive News & Ratings for Vectura Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vectura Group and related companies with's FREE daily email newsletter.